Close menu




January 5th, 2021 | 08:27 CET

BYD, Blackrock Gold, Xpeng - electric cars, where's the limit?

  • Investments
Photo credits: Blackrock Gold Corp.

The disruptive replacement of combustion engines with electric motors is in full swing. Pioneers of e-mobility such as Tesla, BYD, NIO and soon Apple, are overrunning the traditional car manufacturers. The latter have either underestimated the development in recent years or do not have the necessary technical know-how. This development can be seen impressively in both the sales increases and the stock market values. The trend seems unbroken, and there is little to suggest a change in the near future.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: CA09258M1014 , CNE100000296 , US98422D1054

Table of contents:


    Incredible valuations

    Tesla is by far the most valuable carmaker in the world at USD 670 billion, followed by Toyota at USD 215 billion and the German flagship Volkswagen at a comparably meager USD 100 billion. Add to the Tesla competition Fiat Chrysler, Daimler, General Motors, BMW, Honda and Hyundai. Together, they are on par with the Company led by star founder Elon Musk at just under USD 670 billion.

    Of course, this is not reflected in the actual sales or profit figures. Here, Tesla is "still" far behind the competition. Only the fantasy of future profits and absolute market leadership can explain such a high market capitalization.

    Record figures on the assembly line

    Yesterday, Tesla was once again able to report a record number of deliveries. The US electric carmaker delivered more than 180,000 vehicles to customers in the fourth quarter. That was better than analysts' estimates of 173,000 cars. For the year as a whole, Tesla delivered 499,550 vehicles, just missing its self-imposed target of 500,000 units for 2020.

    In the previous year, the figure was 367,500. In addition, the US Company announced that it is on track to build two more production facilities - production at these is scheduled to start before the end of 2021. In addition to the construction of a Gigafactory in Texas's US state, a new Gigafactory is being built near Berlin, which is to produce up to a further 500,000 vehicles per year. Even stronger growth will be sorely needed in the coming years. The same company value as that of the 10 largest carmakers lags enormously.

    Strong competition

    Chinese competitors NIO and Xpeng also reported record results. NIO managed to top its delivery target for the final quarter. In the last three months of the year, 17,353 cars were delivered - a year-on-year increase of 111%. For the year as a whole, NIO delivered some 43,728 vehicles representing a 112.6% increase over the previous year. Xpeng also reported a sharp rise in delivery figures.

    The Chinese manufacturer brought 27,041 cars off the assembly line in the full year 2020, a more than 100% increase on the same period last year. Tesla's biggest competitor, BYD, is also expected to report further record figures. Shares of electric carmakers started the trading day yesterday with double-digit gains but then retreated sharply from the highs. Some air could be taken out of the valuations; this would only be healthy in the long term.

    Rise after correction

    The gold price has corrected in recent months. After its high in August at over USD 2,000, a consolidation of several months below USD 1,800 followed. By dynamically breaking above the USD 1,900 mark, the precious yellow metal is now aiming for the old highs. Gold mining stocks have also corrected well recently and are becoming attractive again for investors. One interesting Company is the gold explorer Blackrock Gold, which is working on two very promising projects in Nevada's US state.

    The first project, Tonopah West, saw positive news at the end of last year. Due to positive results, the Victor gold ore vein had to be enlarged by 480m. In addition, the gold and silver discoveries were significantly above expectations. Thus, in the full year 2020, a total of 14 gold and silver discoveries were achieved with peak four-digit results in grams per ton. Further drill results are still pending for 2021. Should these also turn out positive, the path to becoming a precious metals producer is not far away.

    Hot iron in the fire

    Blackrock Gold's second property is also performing similarly well. At Silver Cloud, the Canadians were able to announce the start of a 3,500-meter drill program. The area is attractive because the geology shows many similarities with the Hollister mine operated by Hecla Mining. Here, the Company is currently evaluating whether Silver Cloud could be the extension of the Hollister mine.

    Management is also planning to transfer the project to a new company as a spin-off. Doing this would once again bring significant fantasy into the share price. Currently, Blackrock Gold is trading at around CAD 1.00. The high was CAD 1.62 in August 2020.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read